Bank of America’s IVERIC bio, Inc. Common Stock ISEE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-1,637,560
| Closed | -$64.4M | – | 8148 |
|
|
2023
Q2 | $64.4M | Buy |
1,637,560
+1,024,205
| +167% | +$36.2M | 0.01% | 1135 |
|
|
2023
Q1 | $14.9M | Buy |
613,355
+102,915
| +20% | +$2.25M | ﹤0.01% | 2420 |
|
|
2022
Q4 | $10.9M | Buy |
510,440
+135,596
| +36% | +$2.89M | ﹤0.01% | 2605 |
|
|
2022
Q3 | $6.72M | Buy |
374,844
+98,400
| +36% | +$1.29M | ﹤0.01% | 3030 |
|
|
2022
Q2 | $2.66M | Sell |
276,444
-104,715
| -27% | -$1.31M | ﹤0.01% | 4045 |
|
|
2022
Q1 | $6.41M | Buy |
381,159
+199,921
| +110% | +$2.95M | ﹤0.01% | 3344 |
|
|
2021
Q4 | $3.03M | Buy |
181,238
+153,421
| +552% | +$2.51M | ﹤0.01% | 4152 |
|
|
2021
Q3 | $451K | Sell |
27,817
-32,114
| -54% | -$349K | ﹤0.01% | 5734 |
|
|
2021
Q2 | $378K | Sell |
59,931
-24,995
| -29% | -$161K | ﹤0.01% | 5639 |
|
|
2021
Q1 | $525K | Buy |
84,926
+44,447
| +110% | +$270K | ﹤0.01% | 5322 |
|
|
2020
Q4 | $280K | Buy |
40,479
+8,753
| +28% | +$56K | ﹤0.01% | 5380 |
|
|
2020
Q3 | $180K | Sell |
31,726
-6,144
| -16% | -$29.3K | ﹤0.01% | 5363 |
|
|
2020
Q2 | $194K | Sell |
37,870
-1,332
| -3% | -$5.55K | ﹤0.01% | 5268 |
|
|
2020
Q1 | $134K | Buy |
39,202
+38,658
| +7,106% | +$226K | ﹤0.01% | 5347 |
|
|
2019
Q4 | $5K | Sell |
544
-4,741
| -90% | -$16.9K | ﹤0.01% | 6776 |
|
|
2019
Q3 | $6K | Buy |
5,285
+4,741
| +872% | +$5.52K | ﹤0.01% | 6827 |
|
|
2019
Q2 | $1K | Hold |
544
| – | – | ﹤0.01% | 7096 |
|
|
2019
Q1 | $1K | Sell |
544
-462
| -46% | -$646 | ﹤0.01% | 7024 |
|
|
2018
Q4 | $1K | Buy |
1,006
+462
| +85% | +$895 | ﹤0.01% | 7013 |
|
|
2018
Q3 | $1K | Hold |
544
| – | – | ﹤0.01% | 7172 |
|
|
2018
Q2 | $1K | Buy |
544
+44
| +9% | +$121 | ﹤0.01% | 7008 |
|
|
2018
Q1 | $1K | Hold |
500
| – | – | ﹤0.01% | 7005 |
|
|
2017
Q4 | $2K | Sell |
500
-11,884
| -96% | -$33.4K | ﹤0.01% | 6875 |
|
|
2017
Q3 | $35K | Sell |
12,384
-46,080
| -79% | -$124K | ﹤0.01% | 6090 |
|
|
2017
Q2 | $150K | Buy |
58,464
+38,026
| +186% | +$104K | ﹤0.01% | 5438 |
|
|
2017
Q1 | $75K | Sell |
20,438
-209,149
| -91% | -$884K | ﹤0.01% | 5753 |
|
|
2016
Q4 | $1.11M | Buy |
229,587
+12,801
| +6% | +$380K | ﹤0.01% | 4262 |
|
|
2016
Q3 | $10M | Sell |
216,786
-17,653
| -8% | -$996K | ﹤0.01% | 2240 |
|
|
2016
Q2 | $12M | Buy |
234,439
+9,366
| +4% | +$465K | ﹤0.01% | 2024 |
|
|
2016
Q1 | $9.51M | Buy |
225,073
+4,095
| +2% | +$209K | ﹤0.01% | 2191 |
|
|
2015
Q4 | $17.4M | Buy |
220,978
+92,933
| +73% | +$5.37M | ﹤0.01% | 1766 |
|
|
2015
Q3 | $5.19M | Buy |
128,045
+105,547
| +469% | +$5.59M | ﹤0.01% | 2846 |
|
|
2015
Q2 | $1.17M | Buy |
22,498
+16,114
| +252% | +$802K | ﹤0.01% | 3968 |
|
|
2015
Q1 | $298K | Sell |
6,384
-3,649
| -36% | -$189K | ﹤0.01% | 4667 |
|
|
2014
Q4 | $450K | Buy |
10,033
+3,767
| +60% | +$158K | ﹤0.01% | 4714 |
|
|
2014
Q3 | $244K | Buy |
6,266
+3,396
| +118% | +$133K | ﹤0.01% | 5212 |
|
|
2014
Q2 | $122K | Buy |
2,870
+2,351
| +453% | +$86.3K | ﹤0.01% | 5970 |
|
|
2014
Q1 | $19K | Buy |
519
+219
| +73% | +$7.39K | ﹤0.01% | 6937 |
|
|
2013
Q4 | $10K | Buy |
+300
| New | +$8.9K | ﹤0.01% | 7291 |
|
Bank of America's ISEE Position: Q3 2023 in Review
Bank of America sold out of IVERIC bio, Inc. Common Stock (ISEE) in Q3 2023, closing a stake of 1,637,560 shares — an estimated $64.4M sold.
Bank of America first reported a position in ISEE in Q4 2013 and held it in 39 quarters. The position peaked at $64.4M in Q2 2023. 0 funds tracked by Wall St. Rank hold ISEE as of Q3 2023.
- Bank of America reported no remaining IVERIC bio, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
- Bank of America sold 1,637,560 IVERIC bio, Inc. Common Stock shares in Q3 2023, an estimated $64.4M.
- Bank of America first reported a position in IVERIC bio, Inc. Common Stock in Q4 2013 and held it in 39 quarters.
- Bank of America's IVERIC bio, Inc. Common Stock position peaked at $64.4M in Q2 2023.
- 0 funds tracked by Wall St. Rank held IVERIC bio, Inc. Common Stock as of Q3 2023.
Based on Bank of America's 13F filing for Q3 2023, filed 14 Nov 2023.